This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.

This study has been completed.
Information provided by (Responsible Party):
Boehringer Ingelheim Identifier:
First received: September 14, 2009
Last updated: February 24, 2014
Last verified: February 2014
Results First Received: May 30, 2012  
Study Type: Observational
Study Design: Observational Model: Cohort;   Time Perspective: Prospective
Condition: HIV Infections
Interventions: Drug: Tipranavir
Drug: ritonavir

  Participant Flow

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Aptivus and Ritonavir TPV/r means Treated with Tipranavir (Aptivus) 500mg twice daily and low-dose ritonavir

Baseline Measures
   Aptivus and Ritonavir 
Overall Participants Analyzed 
[Units: Participants]
Age [1] 
[Units: Years]
Mean (Standard Deviation)
 25.5  (10.4) 
[1] Age is available for 41 patients.
[Units: Number]
Female   19 
Male   23 
Baseline HIV RNA values 
[Units: Participants]
<= 50 copies/ml   0 
51 - <1,000 copies/ml   1 
1,000 - <10,000 copies/ml   5 
10,000 - <100,000 copies/ml   13 
100,000 - <1,000,000 copies/ml   12 
>= 1,000,000 copies/ml   0 
Missing   11 
Baseline CD4+ count 
[Units: Participants]
<= 50 cells/mm^3   2 
51 - <251 cells/mm^3   19 
251 - <451 cells/mm^3   13 
>= 451 cells/mm^3   8 

  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Patients Reporting Adverse Events (AE)   [ Time Frame: 48 weeks ]

2.  Secondary:   Virologic Response   [ Time Frame: 48 weeks ]

3.  Secondary:   Change in CD4+ Cell Count From Baseline at Week 48   [ Time Frame: 48 weeks ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information